Business Wire

Cybin and Kernel Announce Results from Kernel Flow ® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

LOS ANGELES & TORONTO--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, and Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), a biopharmaceutical company focused on progressing “Psychedelics ...
ksn.com

AppliedVR and Kernel Flow Announce Clinical Results Evaluating How Brain Changes During Virtual Reality Treatment of Chronic Pain

New feasibility study indicates that VR has the potential to drive physiological changes in the body and brain associated with pain relief LOS ANGELES, Feb. 8, 2024 /PRNewswire/ -- AppliedVR ®, a ...
The Globe and Mail

Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ® today announced key highlights from the completed ...
Nasdaq

Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

LOS ANGELES--(BUSINESS WIRE)-- Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular ...
Financial Post

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

In this single-blind, placebo-controlled study, employing a non-randomized design, the Flow1 system, built with time-domain functional near-infrared spectroscopy (TD-fNIRS) was utilized to measure ...
Business Wire

Kernel Launches Cognitive Decline Study Using Flow2 Neuroimaging Technology

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging technology, is excited to announce the commencement of an observational study focused on characterizing early cognitive ...